Why Beta-Lactams and Macrolides May Work Better Together Than Alone

For decades, combining macrolide antibiotics with beta-lactams was viewed with suspicion. Macrolides such as azithromycin, clarithromycin, and erythromycin halt bacterial protein synthesis by binding the 23S rRNA of the 50S ribosomal subunit, producing a bacteriostatic state. Beta-lactams, by contrast, kill bacteria by blocking penicillin-binding proteins and disrupting cell-wall synthesis. The classical concern was that a static drug would blunt the lethal action of a cidal one, and clinicians generally hesitated to prescribe the two classes together. A comprehensive review published in Frontiers in Cellular and Infection Microbiology now argues that this long-standing caution deserves revision, at least in carefully defined clinical settings.

The review, led by Qiaochun Lu and colleagues at Zhejiang University School of Medicine and partner institutions in China, systematically evaluates both the clinical and mechanistic evidence for beta-lactam–macrolide combination therapy. The authors apply a three-level grading framework to distinguish established findings from probable or merely hypothesized ones. Their central conclusion is nuanced: the combination shows its clearest benefit in adults with severe community-acquired pneumonia, while evidence in non-severe pneumonia and pediatric populations remains inconsistent. Biological synergy, they caution, does not automatically translate into clinical benefit for every patient.

The strongest clinical signal comes from severe community-acquired pneumonia. In the double-blind ACCESS trial, adjunctive clarithromycin added to a beta-lactam significantly improved a composite early endpoint combining symptom reduction and inflammatory markers, reduced new organ failure, and shortened time to discharge alive. A subsequent meta-analysis of randomized trials estimated higher clinical success with macrolide add-on therapy, and a network meta-analysis ranked beta-lactam plus macrolide favorably among empirical strategies for severe disease. Yet the mortality benefit remains suggestive rather than definitive, derived largely from observational data vulnerable to confounding by illness severity and treatment timing.

Outside severe pneumonia, the picture is far less favorable. The cluster-randomized CAP-START trial found beta-lactam monotherapy noninferior to combination strategies for 90-day mortality in non-ICU wards, and an open-label randomized trial in moderately severe pneumonia failed to establish monotherapy inferiority. Pediatric cohort data, including a study of more than 2,500 hospitalized children, showed no routine outcome benefit from empirical macrolide combination therapy. Guidelines reflect this unevenness: the 2019 ATS/IDSA recommendations support the combination for hospitalized and severe pneumonia, while the 2023 European guideline conditionally favors adding a macrolide over a fluoroquinolone in severe disease but rates the evidence as very low certainty.

What explains the apparent synergy at the mechanistic level? The review identifies several complementary pathways. The most established is target complementarity: beta-lactams inhibit peptidoglycan crosslinking while macrolides block translation, so the two drugs attack distinct essential processes simultaneously. A second, more speculative hypothesis holds that beta-lactam-induced cell-wall injury increases macrolide penetration into the bacterial cell. Evidence for this comes from indirect models, such as bacteriophage-derived endolysins that disrupt peptidoglycan and enhance macrolide activity, but direct demonstration with conventional clinical combinations is lacking.

Additional mechanisms operate at subinhibitory concentrations. In vitro studies show that azithromycin downregulates the MexAB-OprM efflux pump in Pseudomonas aeruginosa and suppresses quorum-sensing signals of the las and rhl systems, reducing production of virulence factors such as elastase, rhamnolipids, and pyocyanin. In serial-passage and animal models, azithromycin repressed translation of the stress-response regulator rpoS and delayed emergence of resistance to ceftazidime-avibactam. Macrolides also alter biofilm matrix composition and alginate production, potentially exposing proliferating bacteria to beta-lactam activity. These findings lend biological plausibility to the combination but remain largely preclinical.

Host-directed effects may be equally important. In the ACCESS trial, clarithromycin modulated tumor necrosis factor-alpha responses in stimulated immune cells and altered circulating interleukin-10 and the IL-8/IL-10 balance, suggesting correction of infection-related immune dysregulation. Preclinical work indicates macrolides can dampen pro-inflammatory macrophage activation, promote an M2-like phenotype with enhanced phagocytosis, and influence dendritic-cell and T-cell responses. The authors grade cytokine modulation as supported by patient-derived data, while broader immune effects remain probable based on animal and ex vivo evidence.

The review also emphasizes that the three macrolides are not interchangeable. Clarithromycin carries the only direct randomized evidence from the ACCESS trial, which cannot be extrapolated to azithromycin or erythromycin. Azithromycin’s combination evidence is essentially preclinical, and its use in pneumonia regimens rests primarily on atypical-pathogen coverage rather than proven synergy. Erythromycin has virtually no contemporary evidence for acute combination therapy and is limited by gastrointestinal intolerance and strong CYP3A4 inhibition. All macrolides can prolong the QT interval, and large pharmacoepidemiologic studies have linked macrolide therapy to elevated cardiovascular risk, although the ACCESS trial itself found no increase in adverse events.

Resistance considerations further complicate the picture. erm-mediated ribosomal methylation generally abolishes macrolide activity, and a beta-lactam partner cannot restore susceptibility, a critical point when atypical coverage is the goal. Macrolide exposure also selects for resistance in colonizing microbiota and environmental reservoirs. The authors advocate an antibiotic time-out at 48 to 72 hours, using clinical response and microbiological findings to de-escalate to beta-lactam monotherapy once atypical infection becomes unlikely. Pharmacokinetic differences matter too: beta-lactams require sustained concentrations above the minimum inhibitory concentration, while macrolides achieve high tissue levels with prolonged post-antibiotic effects, a complementarity that may support combination use in severe disease.

The reviewers conclude that beta-lactam–macrolide therapy is a biologically and clinically defensible option for selected severe infections, particularly severe community-acquired pneumonia, but not a universally synergistic strategy. Most proposed molecular pathways are pathogen- and exposure-specific, and several remain hypothetical. Future research should link defined drug exposures and pathogen-specific mechanisms to patient-centered outcomes, stratified by severity, macrolide agent, and resistance phenotype. Until then, the combination should be reserved for the right patients, at the right time, with the right drugs—rather than extrapolated indiscriminately across the infectious-disease spectrum.

Subject of Research: Mechanisms and clinical evidence for synergistic interactions between macrolide and beta-lactam antibiotics in bacterial infections

Article Title: Mechanistic insights into the synergistic interactions between macrolides and beta-lactams in bacterial infections

Article References: Mechanistic insights into the synergistic interactions between macrolides and beta-lactams in bacterial infections. (n.d.). https://doi.org/10.3389/fcimb.2026.1894766

Image Credits: AI Generated

DOI: 10.3389/fcimb.2026.1894766

Keywords: macrolides, beta-lactams, antibiotic synergy, community-acquired pneumonia, clarithromycin, azithromycin, antimicrobial resistance, biofilms, quorum sensing, immunomodulation, pharmacokinetics, antibiotic stewardship